TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 06/11/24

The New Expanded Partnership Will Aim to Support the Dismantling of Systemic Barriers to Equity and Help Strengthen the Health Workforce in Massachusetts The Existing Global Partnership Has Provided Screening and Diagnostic Services to Over 8 Million People in Community Settings ...

2024-06-06 06:19:20 ET Summary Takeda Pharmaceutical Company's shares have not been able to overcome overhead resistance and are likely to test their October 2022 lows. TAK stock has declined by over 17% since our previous commentary, while the S&P 500 has rallied over 36%. ...

2024-06-03 18:42:13 ET More on Sanofi Sanofi Q1: Wait And See For Now (Downgrade) Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade) Sanofi 2024 Q1 - Results - Earnings Call Presentation Regeneron/ Sanofi say FDA has delayed Dupixe...

2024-06-03 14:24:35 ET More on Pfizer, Takeda Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Turning The Corner (Rating Upgrade) Pfizer: Down To A Historically Low Valuation - Is It A Buy? Takeda gets positive opinion from EU regulat...

– Phase 2b Trial Demonstrated Statistically Significant and Clinically Meaningful Improvements Across Primary and all Secondary Endpoints up to 8 Weeks – TAK-861 is the First Oral Orexin Receptor 2 Agonist to Potentially Address the Underlying Pathophysiology of NT1 ...

− Four-year Analysis Conducted by GHSG Reported ADCETRIS + ECADD Combination Improved Progression-Free Survival, Showing Superior Efficacy and Tolerable Safety Profile in Patients with Newly Diagnosed Stage IIb/III/IV Classical Hodgkin Lymphoma vs eBEACOPP, a Current Standard of Care i...

2024-05-31 13:23:35 ET More on Takeda Pharmaceutical Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript Takeda Pharmaceutical Company Limited 2023 Q4 - Results - Earnings Call Presentation Takeda Pharmaceutical: Eohilia's FDA Approv...

cTTP Is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90% 1,2 If Approved in the European Union, rADAMTS13 Will Be the First and Only Recombinant ADAMTS13 Enzyme Replacement The...

2024-05-27 10:05:29 ET Summary Arrowhead Pharmaceuticals' stock has dropped more than 70% from its June 2021 high, causing concerns about its near-term outlook. The company's lead therapy, plozasiran, is currently behind Ionis Pharmaceuticals' olezarsen for two hypertriglyceridemi...

2024-05-26 02:45:00 ET Summary Jiangsu Hengrui Medicine out-licenses global rights for its GLP-1 candidates to US startup Hercules in a deal worth up to $6 billion. Shanghai Degron Therapeutics partners with Takeda to identify multiple targets in oncology, neuroscience, and inflam...